Unlike specific EGFR mutations found in lung cancer that determine tumor sensitivity/resistance to the EGFR tyrosine kinase inhibitor gefitinib, such mutations are uncommon in breast cancer cells [108, 109]. This evidence concerns the gene EGFR and neoplasm.